Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23010IDB-L5

Select Item

Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions.

Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into “warm” and “cold” types, depending on the temperature at which the antibodies bind to red blood cells. Warm AIHA is more common and occurs at body temperature, while cold AIHA happens at lower temperatures. Treatment may involve corticosteroids, immunosuppressive drugs, blood transfusions, and, in severe cases, splenectomy. Management aims to control the immune response and alleviate anemia-related symptoms.

The Acquired (Autoimmune) Hemolytic Anemia drugs in development market research report provide comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Acquired (Autoimmune) Hemolytic Anemia
Key Targets
· Hemoglobin Subunit Beta; Hemoglobin Subunit Gamma 1; B Lymphocyte Antigen CD19; B Cell Lymphoma/Leukemia 11A; Complement C1s Subcomponent; Hemoglobin Subunit Gamma 2; IgG Receptor FcRn Large Subunit p51; Transmembrane Protease Serine 6; Tyrosine Protein Kinase SYK; and P Selectin
Key Mechanisms of Action
· Hemoglobin Subunit Beta Activator; Hemoglobin Subunit Gamma 1 Activator; Complement C1s Subcomponent Inhibitor; B Cell Lymphoma/Leukemia 11A Inhibitor; IgG Receptor FcRn Large Subunit p51 Antagonist; Transmembrane Protease Serine 6 Inhibitor; Tumor Necrosis Factor Receptor Superfamily Member 13C Antagonist; Tyrosine Protein Kinase SYK Inhibitor; Pyruvate Kinase PKLR Activator; and Solute Carrier Family 40 Member 1 Inhibitor
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Parenteral; Topical; Intramedullary; and Ophthalmic
Key Molecule Types
· Gene-Modified Cell Therapy; Small Molecule; Monoclonal Antibody; Gene Therapy; Fusion Protein; Cell Therapy; Biologic; Antisense RNAi Oligonucleotide; Recombinant Protein; and Oligonucleotide
Major Companies
· Novartis AG; Novo Nordisk AS; Guangzhou Reforgene Medicine Co Ltd; Genmedicn Biopharma Ltd; BRL Medicine Inc; Cellics Therapeutics Inc; Annexon Inc; Shenzhen Hemogen Gene Biotechnology Co Ltd; Pfizer Inc; and Vertex Pharmaceuticals Inc

Scope

  • Therapeutics in Development: Covering 99 molecules, with 92 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Acquired (Autoimmune) Hemolytic Anemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Acquired (Autoimmune) Hemolytic Anemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acquired (Autoimmune) Hemolytic Anemia treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Abfero Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Allife Medical Science and Technology Co Ltd
Alpine Immune Sciences Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Argenx SE
Ariya Bio
ASC Therapeutics Inc
Ascentage Pharma Group Inc
Asklepion Pharmaceuticals LLC
Beam Therapeutics Inc
Bellicum Pharmaceuticals Inc
Biomac Lifesciences Pvt Ltd
BRL Medicine Inc
Cell Source Inc
Cellics Therapeutics Inc
Centre for Stem Cell Research
Cetya Therapeutics Inc
CHA Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
CorrectSequence Therapeutics Co Ltd
CRISPR Therapeutics AG
CSL Ltd
Dianthus Therapeutics Inc
Disc Medicine Inc
EdiGene Inc
Editas Medicine Inc
F. Hoffmann-La Roche Ltd
Fera Pharmaceuticals LLC
Garuda Therapeutics Inc
Genmedicn Biopharma Ltd
Genosco Inc
GlycoMimetics Inc
Guangzhou Reforgene Medicine Co Ltd
HanAll Biopharma Co Ltd
Hartis Pharma SA
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
ImmuneCyte Inc
Invenux LLC
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Johnson & Johnson
Kanglin Biotech Hangzhou Co Ltd
Mabion SA
Mabwell Therapeutics Inc
Merck & Co Inc
Merganser Biotech Inc
Mina Therapeutics Ltd
Monte Rosa Therapeutics Inc
Nanfang Hospital
Nanjing IASO Biotherapeutics Co Ltd
National Jewish Health
Novartis AG
NovelMed Therapeutics Inc
Novo Nordisk AS
NuvOx Pharma LLC
Orchard Therapeutics Plc
Pfizer Inc
Phoenicia Biosciences Inc
Principia Biopharma Inc
Prolong Pharmaceuticals LLC
Rallybio Corp
Rare Partners Srl
Regenacy Pharmaceuticals LLC
Rigel Pharmaceuticals Inc
San Rocco Therapeutics LLC
Sana Biotechnology Inc
Sanofi
Shanghai BDgene Therapeutics Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Vitalgen BioPharma Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Hemogen Gene Biotechnology Co Ltd
Silence Therapeutics Plc
Suzhou GenAssist Therapeutics Co Ltd
Syros Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Taxon Therapeutics Ltd
U.S. National Institutes of Health
University of Oxford
Vertex Pharmaceuticals Inc
Vifor Pharma Management Ltd
Weill Cornell Medical College
Zenas BioPharma (USA) LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Acquired (Autoimmune) Hemolytic Anemia reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 in real time.

  • Access a live Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more